| Home : EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma |
|
Apr 03
2018 |
EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma |
|
TARRYTOWN, N.Y. and PARIS, April 3, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency (EMA) has accepted for review an application for DUPIXENT® (dupilumab) as an add-on maintenance treatment in certain adults... |
|
|
|
| Source:https://www.prnewswire.com/news-releases/ema-to-review-dupixent-dupilumab-as-potential-treatment-for-inadequately-controlled-moderate-to-severe-asthma-300623023.html |
| |
|
Related News
|
» Genom köpet av Autoadapt utökar BraunAbility verksamheten i Europa
» Trump launches Twitter tirade and declares 'DACA is dead'
|
